|
| Baseline features | n | Serum IL-17 | value | Serum VEGF | value | Serum LDH | value |
|
| Age (<60 years/≥60 years) | 13/32 | 64.25 ± 3.35/61.36 ± 3.20 | >0.05 | 245.36 ± 25.12/246.33 ± 24.96 | >0.05 | 325.53 ± 88.47/329.32 ± 95.82 | >0.05 |
| Gender (male/female) | 21/24 | 62.20 ± 2.87/62.11 ± 3.02 | >0.05 | 244.33 ± 24.69/245.98 ± 25.13 | >0.05 | 349.73 ± 13.78/345.83 ± 17.52 | >0.05 |
| Tumor TNM stage (stage I-II/stage III/stage IV) | 23/15/7 | 53.58 ± 3.12/64.25 ± 4.12/72.99 ± 3.96 | <0.05 | 231.62 ± 25.14/248.36 ± 26.66/267.32 ± 28.14 | <0.05 | 312.44 ± 24.63/341.36 ± 25.76/368.67 ± 79.51 | <0.05 |
| Lymph node metastasis (yes/no) | 25/20 | 62.61 ± 3.77/62.21 ± 3.51 | >0.05 | 245.31 ± 26.20/243.77 ± 27.12 | >0.05 | 321.6 ± 78.94/327.6 ± 81.62 | >0.05 |
| Differentiation (low differentiation/medium-high differentiation) | 27/18 | 61.25 ± 3.53/63.99 ± 3.62 | >0.05 | 244.25 ± 25.74/242.39 ± 26.14 | >0.05 | 331.11 ± 72.67/328.42 ± 66.51 | >0.05 |
| Pathological type (adenocarcinoma/adenosquamous/squamous carcinoma) | 28/13/4 | 62.77 ± 3.62/62.98 ± 3.54/63.10 ± 3.62 | >0.05 | 242.83 ± 26.12/244.96 ± 25.38 | >0.05 | 332.83 ± 26.12/334.96 ± 25.38 | >0.05 |
|
